Search research articles
Contact Us
Filters
Showing results (1-10 of 47) with videos related to
Page
of 5
Sort By:
Current Oncology Reports
|
July 16, 2021
Current Management of Refractory Germ Cell Tumors
Omar Abughanimeh, Benjamin A Teply
Cancers
|
November 27, 2021
Biomarkers for Treatment Response in Advanced Prostate Cancer
Samia Asif, Benjamin A Teply
Expert Review of Clinical Pharmacology
|
October 26, 2022
The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations
Benjamin A Teply, Emmanuel S Antonarakis
Journal of Solid Tumors
|
November 19, 2014
Systemic therapy for bladder cancer - a medical oncologist's perspective
Benjamin A Teply, Jenny J Kim
Current Opinion in Endocrinology, Diabetes, and Obesity
|
March 16, 2016
Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer
Benjamin A Teply, Emmanuel S Antonarakis
Expert Review of Clinical Pharmacology
|
June 3, 2017
Treatment strategies for DNA repair-deficient prostate cancer
Benjamin A Teply, Emmanuel S Antonarakis
Oncology (Williston Park, N.Y.)
|
November 12, 2014
Identification and management of toxicities from immune checkpoint-blocking drugs
Benjamin A Teply, Evan J Lipson
Indian Journal of Urology : IJU : Journal of the Urological Society of India
|
November 16, 2016
Chemotherapy options in castration-resistant prostate cancer
Benjamin A Teply, Ralph J Hauke
The Prostate
|
March 27, 2023
A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease
Jonathan Q Trinh, Subodh M Lele, Benjamin A Teply
JCO Oncology Practice
|
August 5, 2021
Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors
Mridula Krishnan, Pooja Kasinath, Robin High, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 47) with videos related to
Sort By:
Page
of 5
Current Oncology Reports
|
July 16, 2021
Current Management of Refractory Germ Cell Tumors
Omar Abughanimeh, Benjamin A Teply
Cancers
|
November 27, 2021
Biomarkers for Treatment Response in Advanced Prostate Cancer
Samia Asif, Benjamin A Teply
Expert Review of Clinical Pharmacology
|
October 26, 2022
The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations
Benjamin A Teply, Emmanuel S Antonarakis
Journal of Solid Tumors
|
November 19, 2014
Systemic therapy for bladder cancer - a medical oncologist's perspective
Benjamin A Teply, Jenny J Kim
Current Opinion in Endocrinology, Diabetes, and Obesity
|
March 16, 2016
Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer
Benjamin A Teply, Emmanuel S Antonarakis
Expert Review of Clinical Pharmacology
|
June 3, 2017
Treatment strategies for DNA repair-deficient prostate cancer
Benjamin A Teply, Emmanuel S Antonarakis
Oncology (Williston Park, N.Y.)
|
November 12, 2014
Identification and management of toxicities from immune checkpoint-blocking drugs
Benjamin A Teply, Evan J Lipson
Indian Journal of Urology : IJU : Journal of the Urological Society of India
|
November 16, 2016
Chemotherapy options in castration-resistant prostate cancer
Benjamin A Teply, Ralph J Hauke
The Prostate
|
March 27, 2023
A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease
Jonathan Q Trinh, Subodh M Lele, Benjamin A Teply
JCO Oncology Practice
|
August 5, 2021
Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors
Mridula Krishnan, Pooja Kasinath, Robin High, et al.
Page
of 5